Last reviewed · How we verify
SL-APO
At a glance
| Generic name | SL-APO |
|---|---|
| Also known as | Kynmobi |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SL-APO CI brief — competitive landscape report
- SL-APO updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI